Surgery Partners (NASDAQ:SGRY) Announces Earnings Results

Surgery Partners (NASDAQ:SGRY) released its earnings results on Monday. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.01, Zacks reports. The company had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $828.09 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. Surgery Partners updated its FY 2025 guidance to EPS.

Surgery Partners Stock Performance

Shares of NASDAQ:SGRY opened at $23.80 on Wednesday. The stock has a market capitalization of $3.03 billion, a price-to-earnings ratio of -49.58, a price-to-earnings-growth ratio of 19.21 and a beta of 2.60. Surgery Partners has a fifty-two week low of $19.50 and a fifty-two week high of $33.97. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. The business’s fifty day moving average price is $23.15 and its two-hundred day moving average price is $26.37.

Insiders Place Their Bets

In other news, CEO Jason Eric Evans sold 26,520 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.65, for a total value of $680,238.00. Following the transaction, the chief executive officer now owns 560,698 shares of the company’s stock, valued at $14,381,903.70. This represents a 4.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO David T. Doherty sold 13,641 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.61, for a total value of $349,346.01. Following the completion of the transaction, the chief financial officer now owns 108,862 shares in the company, valued at $2,787,955.82. This represents a 11.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 96,733 shares of company stock valued at $2,480,106. 2.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

SGRY has been the subject of several research reports. JPMorgan Chase & Co. decreased their price target on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a report on Tuesday, December 3rd. Royal Bank of Canada lowered their price target on shares of Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. Bank of America started coverage on shares of Surgery Partners in a research note on Monday, December 16th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Macquarie reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Surgery Partners in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $36.56.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.